The rapid evolution of RNA therapeutics has expanded the treatment landscape for Central Nervous System (CNS) disorders. However, achieving efficient, region-specific delivery remains a primary translational challenge. Factors such as the Blood-Brain Barrier (BBB), complex Cerebrospinal Fluid (CSF) dynamics, and heterogeneous cortical architecture often result in inconsistent distribution profiles.
To mitigate these risks, selecting the appropriate preclinical model and technical execution is critical for clinical success.
Why Non-Human Primates (NHPs) are the Gold Standard
Non-human primates (NHPs) are the most predictive preclinical species for CNS drug development. Their gyrencephalic brain structure, CSF circulation patterns, and immunological profiles closely mirror human physiology-unlike rodent models.
For sponsors developing mRNA, siRNA, or ASO modalities, NHP biodistribution studies provide high-fidelity data on:
- Regional Brain Exposure: Mapping nucleic acid concentration across cortical and subcortical regions.
- Intrathecal (IT) Delivery Kinetics: Evaluating the efficiency of LNP-based systems or viral vectors.
- Safety Margins: Assessing early neuro-inflammatory responses and off-target effects.
Precision Intrathecal (IT) Administration Strategies
At PRISYS Biotech, CNS biodistribution studies prioritize translational accuracy over mere procedural execution. Our protocols utilize advanced delivery techniques to ensure data reproducibility:
- Imaging-Guided Access: IT administration is performed under real-time imaging guidance to ensure precise access to the lumbar or cisterna magna space.
- Catheterization for Sustained Exposure: For protocols requiring repeated dosing or serial CSF sampling, implanted catheter systems allow for controlled delivery and longitudinal PK/PD monitoring.
- Integrated Monitoring: In-life assessments combine CSF biomarker analysis with early safety readouts within a single experimental framework.
Quantitative Bioanalysis and Spatial Mapping
The value of a biodistribution study lies in its analytical depth. Following perfusion-based tissue preservation, we employ a rigorous post-life workflow:
| Feature | Methodology |
| Structural Integrity | Optimized whole-brain processing for high-resolution analysis. |
| Quantitative Mapping | Region-specific micro-dissection of cortical and subcortical structures. |
| Spatial Visualization | Fluorescence-based imaging to localize labeled RNA constructs. |
| Molecular Correlation | Integration of qPCR or protein-level assays to link tissue exposure with target engagement. |
Operational Excellence: From Screening to Reporting
Our exploratory, non-GLP study designs balance scientific rigor with operational agility. We streamline animal screening, acclimation, and dosing to ensure data continuity and scheduling efficiency. The primary objective is to generate interpretable, region-specific data that directly informs formulation optimization and clinical route selection.
Infrastructure and Accreditation
With over 15 years of NHP research expertise and an AAALAC-accredited facility, PRISYS Biotech integrates clinical-grade imaging-including MRI and multi-slice CT-into the translational workflow. This allows for:
- Precise procedure planning and anatomical confirmation.
- Longitudinal monitoring of CNS morphology.
- Reduced uncertainty during early-stage CNS program development.
De-risking Clinical Translation
For sponsors advancing RNA therapeutics toward First-in-Human (FIH) trials, NHP biodistribution data is an essential component of the regulatory package. By providing a clear map of how a therapeutic behaves in a primate CNS, we help de-risk clinical trial design and regulatory interactions.
Contact PRISYS Biotech today to discuss how our NHP platforms can align with your program's translational objectives.
